Last quarter (Q2 2023), Spruce Biosciences's total revenue was $2.20M, an increase of Infinity% from the same quarter last year. In Q2, Spruce Biosciences's net income was $-12.79M. See Spruce Biosciences’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	$ 4.20M	-	-	$ 0.00	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	$ 4.20M	-	-	-	-	-
Operating Expense	$ 30.75M	$ 47.28M	$ 42.07M	$ 29.42M	$ 13.11M	$ 9.97M
Operating Income	$ -50.80M	$ -47.28M	$ -42.07M	$ -29.42M	$ -13.11M	$ -9.97M
Net Non Operating Interest Income Expense	$ 2.84M	$ 1.10M	$ -226.00K	$ -323.00K	$ -65.00K	$ 0.00
Other Income Expense	$ -588.00K	$ -750.00K	$ -119.00K	$ 200.00K	$ 84.00K	$ 114.00K
Pretax Income	$ -48.09M	$ -46.18M	$ -42.29M	$ -29.54M	$ -13.09M	$ -9.86M
Tax Provision	-	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -48.09M	$ -46.18M	$ -42.29M	$ -29.54M	$ -13.09M	$ -9.86M
Basic EPS	$ -2.68	$ -1.96	$ -1.81	$ -4.93	$ -2.67	$ -2.01
Diluted EPS	$ -1.67	$ -1.96	$ -1.81	$ -4.93	$ -2.67	$ -2.01
Basic Average Shares	$ 119.54M	$ 23.53M	$ 23.36M	$ 5.99M	$ 4.89M	$ 4.89M
Diluted Average Shares	$ 119.54M	$ 23.53M	$ 23.36M	$ 5.99M	$ 4.89M	$ 4.89M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 30.75M	$ 47.28M	$ 42.07M	$ 29.42M	$ 13.11M	$ 9.97M
Net Income From Continuing And Discontinued Operation	$ -48.16M	$ -46.18M	$ -42.29M	$ -29.54M	$ -13.09M	$ -9.86M
Normalized Income	$ -11.40M	-	-	$ -29.54M	$ -13.09M	$ -9.86M
Interest Expense	$ 110.00K	-	-	$ 323.00K	$ 65.00K	$ 0.00
EBIT	$ -49.39M	$ -45.76M	$ -42.07M	$ -29.22M	$ -13.02M	$ -9.86M
EBITDA	$ -36.83M	$ -45.31M	$ -41.56M	$ -29.18M	$ -13.01M	$ -9.86M

Currency in USD

Spruce Biosciences Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing